How to select and combine oral agents for patients with type 2 diabetes mellitus

American Journal of Medicine

Volumn 118, Issue 5 SUPPL., 2005, Pages 4-13

  Chipkin, Stuart R ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Combination therapy; Oral agents

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; C PEPTIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; PROINSULIN; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ARTICLE; COMBINATION CHEMOTHERAPY; DIABETES CONTROL; DISEASE DURATION; DRUG COST; DRUG EFFICACY; EDEMA; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; LIPID BLOOD LEVEL; MEDICAL DECISION MAKING; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PEER REVIEW; POSTPRANDIAL STATE; PRIORITY JOURNAL; SIDE EFFECT; STROKE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT GAIN;

EID: 17844410907     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.04.010     Document Type: Article

References (24)

1. UK Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
2. S.E. Inzucchi Oral antihyperglycemic therapy for type 2 diabetes JAMA 287 2002 360 372
3. American Diabetes Association Standards of medical care in diabetes Diabetes Care 28 suppl 1 2005 S4 S36
4. A.J. Garber, T.G. Duncan, A.M. Goodman Efficacy of metformin in type II diabetes results of a double-blind placebo-controlled, dose response trial Am J Med 103 1997 491 497
5. M.S. Rendell, N.B. Glazer, Z. Ye Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with type 2 diabetes influence of prior antidiabetic drug regimen J Diabetes Complications 17 2000 211 217
6. Diabetes Medical Guidelines Task Force American Association of Clinical Endocrinologists American College of Endocrinology Medical guidelines for the management of diabetes mellitus the AACE system of intensive diabetes self-management--2002 update Endocr Pract 8 suppl 1 2002 40 65
7. H. Koshiyama, D. Shimono, N. Kuwamura Rapid communication inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes J Clin Endocrinol Metab 86 2001 3452 3456
8. A.A. Parulkar, M.L. Pendergrass, R. Granda-Ayala Nonhypoglycemic effects of thiazolidinediones Ann Intern Med 134 2001 61 71
9. UK Prospective Diabetes Study Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes Lancet 352 1998 854 865
10. K. Neeser, G. Lubben, U. Siebert, W. Schramm Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a German statutory healthcare perspective Pharmacoeconomics 22 2004 321 344
11. R. Drummond Thyroid storm [editorial] JAMA 277 1997 1238 1243
12. S.A. Garfield, S. Malozowski, M.H. Chin Diabetes Mellitus Interagency Coordinating Committee Translation Conference Working Group Considerations for diabetes translational research in real-world settings Diabetes Care 26 2003 2670 2674
13. R.A. DeFronzo, A.M. Goodman Multicenter Metformin Study Group Efficacy of metformin in patients with non-insulin dependent diabetes mellitus N Engl J Med 333 1995 541 549
14. UK Prospective Diabetes Study Group UK prospective study of therapies of maturity-onset diabetes. I. Effect of diet, sulphonylurea insulin or biguanide therapy on fasting plasma glucose and body weight over one year Diabetologia 24 1983 404 411
15. S.E. Inzucchi, D.G. Maggs, G.R. Spollett Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus N Engl J Med 338 1998 867 872
16. B. Willms, D. Ruge Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas a randomized, placebo-controlled study [published correction appears in Diabet Med. 2000;17:332] Diabet Med 16 1999 755 761
17. P. Raskin, L. Klaff, J. McGill Efficacy and safety of combination therapy repaglinide plus metformin versus nateglinide plus metformin Diabetes Care 26 2003 2063 2068
18. M.M. Hanefield, P. Brunetti, G.H. Scherthaner One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes Diabetes Care 27 2004 141 147
19. I. Moules, G. Edwards, S. Mariz Two-year efficacy of the addition of pioglitazone to sulfonylurea therapy in patients with T2DM Diabetes 53 suppl 2 2004 A139 Abstract 584-P
20. S. Mariz, R. Urquhart, I. Moules Effects of pioglitazone addition to metformin or sulfonylurea therapy on serum lipids in patients with T2DM--2-year data Diabetes 53 suppl 2 2004 A137 Abstract 578-P
21. G. Edwards, R. Urquhart, I. Moules Two-year efficacy of pioglitazone versus gliclazide addition to metformin therapy in T2DM Diabetes 53 suppl 2 2004 A475 Abstract 1986-PO
22. J. Rosenstock, B.J. Goldstein, M.J. Wooddell Greater benefits of rosiglitazone (RSG) added to submaximal dose of metformin (MET) compared to maximizing metformin dose in type 2 diabetes mellitus (T2DM) patients Diabetes 53 suppl 2 2004 A144 Abstract 608-P
23. P.N. Weissman, B.J. Goldstein, J.C. Campbell Rosiglitazone plus metformin combination effects on CV risk markers suggest potential CV benefits in type 2 diabetic patients Diabetes 53 suppl 2 2004 A28 Abstract 121-OR
24. Drug cost data for 2004. Available at: http://www.drugstore.com/pharmacy/ drugindex/default.asp?trx/3888. Accessed June 2004.